Immune Microenvironment and Immunotherapy in Pancreatic Cancer: a Narrative Review

Xiaoning Yu,Si Shi,Xianjun Yu

DOI: https://doi.org/10.21037/pcm-22-55

2022-01-01

Precision Cancer Medicine

Abstract:Background and Objective: Pancreatic cancer is a malignancy of the digestive system which is difficult to diagnose and treat. About 90% of pancreatic cancer are ductal adenocarcinomas originating from the glandular ducts’ epithelium. Currently, many anti-tumor drugs have a limited effect due to the pancreatic cancer immune microenvironment, which is an over-fibrous dense matrix environment formed by pancreatic stellate cells, cancer-associated fibroblasts, immune cells, and extracellular stromal. This microenvironment and its interaction with surrounding tissues is a major target for future anti-pancreatic cancer therapies. This paper reviews the research progress related to the immune microenvironment of pancreatic cancer in recent years, discusses its role in pancreatic cancer, and introduces related immunotherapies and their efficacy. Methods: A systematic literature search was conducted on the PubMed research engine. Only English literature will be selected to illustrate the progress of the immune microenvironment and related immunotherapy for pancreatic cancer. The publication date of the literature is limited from January 1st, 1990, to July 1st, 2022. Key Content and Findings: There are complex interactions between various types of cells and molecules in the inhibitory immune microenvironment of pancreatic cancer, and many related pieces of research have been reported. A variety of immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, oncolytic virus therapy, and immune checkpoint inhibitors, have been used in clinical practice. Although their mechanisms are very different, it is worth affirming that some representative drugs and therapies have already gained some benefits. Conclusions: Advances in research on the immune microenvironment of pancreatic cancer will pave the way for immunotherapy. Immunotherapies have advantages that traditional therapies do not. Although most immunotherapy is still in the experimental stage, it is undeniable that in the future, it will be an important way to treat pancreatic cancer.